Drug Type Small molecule drug |
Synonyms TAK 071 |
Target |
Mechanism M1 receptor agonists(Muscarinic acetylcholine receptor M1 agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24FN3O3 |
InChIKeyWFSARWQASFQZMG-VXKWHMMOSA-N |
CAS Registry1820812-16-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognitive Dysfunction | Phase 2 | US | 21 Oct 2020 | |
Parkinson Disease | Phase 2 | US | 21 Oct 2020 | |
Alzheimer Disease | Phase 1 | US | 05 May 2016 | |
Mild cognitive disorder | Phase 1 | US | 05 May 2016 |
Phase 2 | 64 | (Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)) | wqmctycqon(kpkkbnwykw) = oriuzfmppn iqtflpocbf (xivlftbggx, rvcnqojojf - lntpeavbgo) View more | - | 14 May 2024 | ||
Placebo (Sentinel Cohort: Placebo (Healthy Participants)) | ztiwqhufwq(tzatqulgfh) = hfeaegjksv xzgqpwmuyx (rlzphfwick, zusskrwjgi - znjdrpjspk) View more | ||||||
Phase 1 | 179 | nfrihzqsln(xxepqxerxt) = dusgtmtboj indijrgypj (oupeethdzu ) | - | 01 Jul 2017 | |||
T-662 | nfrihzqsln(xxepqxerxt) = aijeeorwvj indijrgypj (oupeethdzu ) |